AYTU BIOPHARMA, INC. - 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026 (Fiscal Q3 2026). Aytu BioPharma, Inc. is a pharmaceutical company focused on central nervous system (CNS) diseases. The company operates as a single reporting segment following the divestiture of its Consumer Health business in July 2024. Its current portfolio consists of three main areas: EXXUA (gepirone) for major depressive disorder (MDD), an ADHD Portfolio, and a legacy Pediatric Portfolio. The company indefinitely suspended active clinical development programs to focus on commercialization and achieving positive operating cash flows.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2026 | Nine Months Ended Mar 31, 2026 | Balance Sheet (Mar 31, 2026) |
|---|---|---|---|
| Net Revenue | $12.4 million | $41.5 million | - |
| Gross Profit | $7.6 million (61% margin) | $26.4 million (64% margin) | - |
| Net Loss (Continuing Ops) | $(5.6) million | $(14.2) million | - |
| Net Loss Per Share (Basic) | $(0.53) | $(1.42) | - |
| Cash and Equivalents | - | - | $26.7 million |
| Total Debt (Current + Non-Current) | - | - | $11.4 million |
| Working Capital | - | - | $7.4 million |
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased 33% ($6.0 million) in Q3 and 19% ($9.8 million) in the nine-month period compared to the prior year. This was driven by a strategic shift in marketing focus from the ADHD Portfolio to the new EXXUA launch and the entry of a generic competitor for an ADHD product in Q2 2026.
- EXXUA Launch: The company successfully launched EXXUA in Q2 2026, generating $2.4 million in revenue for Q3 and $2.6 million for the nine-month period, partially offsetting declines in other portfolios.
- Operating Expenses: Selling and marketing expenses increased due to EXXUA launch costs. Research and development expenses dropped to zero as development programs were suspended.
- Derivative Warrant Liability: The company recognized a loss of $1.3 million in Q3 and $5.7 million for the nine months due to fair value adjustments on liability-classified warrants. Conversely, the prior year included significant gains from warrant liability adjustments.
- Warrant Reclassification: On March 31, 2026, the company amended certain warrants, resulting in the reclassification of $26.4 million from derivative warrant liabilities to stockholders' equity.
Guidance, Outlook, and Risks
- Strategic Focus: Management is prioritizing the commercialization of EXXUA and the ADHD portfolio while aiming to achieve positive operating cash flows. No specific financial guidance was provided in this filing.
- Legal Proceedings: The company is engaged in patent infringement litigation against Granules Pharmaceuticals regarding a generic version of Adzenys. A court stipulation in June 2025 found infringement, and the trial is scheduled for January 2027.
- Debt Covenants: The company is in compliance with covenants under its Eclipse Loan and Security Agreement. However, failure to comply could result in immediate acceleration of debt.
- Liquidity: The company maintains a revolving credit facility with $3.1 million available as of March 31, 2026. It also has a shelf registration for up to $100 million in securities.
- Risks: Key risks include the competitive landscape (generic entry), payer mix pressures, supply chain disruptions, and the success of the EXXUA commercialization.
Investor Verification Checklist
- EXXUA Commercialization: Verify the trajectory of EXXUA sales and market penetration against the $35 million revenue threshold required to trigger increased milestone payments.
- Generic Competition: Monitor the status of the Granules litigation and the potential impact of generic Adzenys on the ADHD Portfolio revenue.
- Warrant Liability Volatility: Assess the remaining $2.2 million in derivative warrant liabilities and the potential for future fair value adjustments impacting net income.
- Cash Burn Rate: Review the net cash used in operating activities ($1.1 million for nine months) against the current cash balance ($26.7 million) to estimate runway without additional financing.
- Debt Obligations: Confirm the repayment schedule for the Eclipse Term Loan ($11.6 million principal) and the impact of interest rates (SOFR + 7.0%) on future cash flows.